Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update

Innovative Eyewear (LUCY) jumped 42% after the company reported preliminary second-quarter net sales that exceeded its own guidance, though it did not disclose exact figures. Seer (SEER) surged 28% on news that it had received a preliminary, non-binding acquisition proposal from an unnamed bidder. Orthofix (OFIX) and Enovis (ENOV) each rose more than 10% after the Centers for Medicare and Medicaid Services reversed a reimbursement policy that had pressured the orthopedic sector.

Innovative Eyewear said the preliminary results reflected strong demand for its smart eyewear line, particularly the Lucyd Lyte model. The company expects to report full second-quarter earnings next month. Seer confirmed it received the takeover proposal and said its board would evaluate the approach. The proteomics firm did not name the potential acquirer or disclose terms.

The CMS update reversed a 2024 rule that had reduced reimbursement for certain orthopedic procedures. Orthofix and Enovis, which generate a significant portion of revenue from the affected procedures, had been under pressure since the original policy. The reversal removed a key headwind for both companies. Orthofix said it was reviewing the CMS announcement and would provide an update on the financial impact in its next earnings call.

The moves in Orthofix and Enovis were among the largest single-day gains for orthopedic stocks in months. The sector had been broadly lower since the 2024 policy change, which led to a drop in procedure volumes and raised concerns about pricing power. The reversal does not restore full reimbursement but analysts at several firms said it could signal a more favorable regulatory environment for medical devices.

Seer's takeover proposal adds to a growing wave of M&A in the life-sciences tools space. The company had been viewed as a potential target given its proprietary proteomics platform and a market cap that had fallen sharply from its peak. The proposal sent shares back toward levels not seen since early 2023.

Innovative Eyewear's sales beat stands out in a small-cap medtech sector that has faced weak consumer spending. The company's smart glasses are sold directly to consumers, and the preliminary numbers suggest demand may be picking up ahead of the back-to-school season. The company did not provide further details beyond the preliminary announcement.